4 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 1 | 1 | Terminated 1 |
Follow T-cell Large Granular Lymphocyte Leukemia: new trials by email Literature Review of T-cell Large Granular Lymphocyte Leukemia trials Research Report on T-cell Large Granular Lymphocyte Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis sunitinib malate - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 14 | 2006-09-01 | 2014-05-28 |
| Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia tipifarnib, laboratory biomarker analysis - Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2006-06-02 | 2017-04-05 |
Leukemia, Large Granular Lymphocytic (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia, Hairy Cell (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Burkitt Lymphoma (2) · Immunoblastic Lymphadenopathy (2) · Intraocular Lymphoma (2) · Leukemia, Prolymphocytic (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Extranodal NK-T-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, Large-Cell, Immunoblastic (2) · Lymphoma, Mantle-Cell (2)
Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukemia (4) · Leukemia, B-Cell (4) · Leukemia, Lymphoid (4) · Leukemia, T-Cell (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Pathologic Processes (4)
Rituximab (2) · Brentuximab Vedotin (1) · Lenalidomide (1) · Sunitinib (1) · tipifarnib (1)
National Cancer Institute (NCI) (2) · Fred Hutchinson Cancer Center (1) · Northwestern University (1)
United States (4)
Adam Petrich, MD (1) · Mohamed Sorror (1) · Srdan Verstovsek (1) · Thomas Loughran (1)
N01CM62202 (1), P30CA015704 (1), U01CA062502 (1)